Clinical course of patients with aplastic anemia or myelodysplastic syndrome associated with persistent neutropenia

Shinichi Kako, Hideki Nakasone, Hiroshi Endo, Kana Sakamoto, Masahiro Ashizawa, Miki Sato, Kiriko Terasako, Misato Kikuchi, Shun ichi Kimura, Shinya Okuda, Rie Yamazaki, Kumi Oshima, Aki Tanihara, Junji Nishida, Kensuke Usuki, Yoshinobu Kanda

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Patients with aplastic anemia (AA) or myelodysplastic syndrome (MDS) often have persistent severe neutropenia and are susceptible to infectious complications. We retrospectively reviewed the clinical course of patients with AA or MDS who had neutropenia (neutrophil count<500/μl) for more than 25days. A total of 46 patients, 11 with AA and 35 with MDS, were included. Twenty-three patients had infectious events (IE), and the cumulative incidence of IE was 30% at 6months and 51% at 1year. The cumulative incidence of IE was 67% at 1year in 30 patients who experienced very severe neutropenia of less than 200/μl. Overall survival in all patients was 76% at 6months and 65% at 1year. In a multivariate analysis, male sex, underlying diseases, and a neutrophil count of less than 200/μl as a time-dependent covariate significantly affected IE. In analyses that excluded patients with AA, male sex was the only factor. In conclusion, severe neutropenia was significantly associated with IE in patients with AA or MDS, and IE might be lethal. When we only considered patients with MDS, the neutrophil count alone could not be used to predict the prognosis.

Original languageEnglish
Pages (from-to)82-88
Number of pages7
JournalHematological Oncology
Volume30
Issue number2
DOIs
Publication statusPublished - 2012 Jun 1
Externally publishedYes

Fingerprint

Aplastic Anemia
Myelodysplastic Syndromes
Neutropenia
Neutrophils
Incidence
Multivariate Analysis
Survival

Keywords

  • Aplastic anemia
  • Myelodysplastic syndrome
  • Neutropenia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Clinical course of patients with aplastic anemia or myelodysplastic syndrome associated with persistent neutropenia. / Kako, Shinichi; Nakasone, Hideki; Endo, Hiroshi; Sakamoto, Kana; Ashizawa, Masahiro; Sato, Miki; Terasako, Kiriko; Kikuchi, Misato; Kimura, Shun ichi; Okuda, Shinya; Yamazaki, Rie; Oshima, Kumi; Tanihara, Aki; Nishida, Junji; Usuki, Kensuke; Kanda, Yoshinobu.

In: Hematological Oncology, Vol. 30, No. 2, 01.06.2012, p. 82-88.

Research output: Contribution to journalArticle

Kako, S, Nakasone, H, Endo, H, Sakamoto, K, Ashizawa, M, Sato, M, Terasako, K, Kikuchi, M, Kimura, SI, Okuda, S, Yamazaki, R, Oshima, K, Tanihara, A, Nishida, J, Usuki, K & Kanda, Y 2012, 'Clinical course of patients with aplastic anemia or myelodysplastic syndrome associated with persistent neutropenia', Hematological Oncology, vol. 30, no. 2, pp. 82-88. https://doi.org/10.1002/hon.1001
Kako, Shinichi ; Nakasone, Hideki ; Endo, Hiroshi ; Sakamoto, Kana ; Ashizawa, Masahiro ; Sato, Miki ; Terasako, Kiriko ; Kikuchi, Misato ; Kimura, Shun ichi ; Okuda, Shinya ; Yamazaki, Rie ; Oshima, Kumi ; Tanihara, Aki ; Nishida, Junji ; Usuki, Kensuke ; Kanda, Yoshinobu. / Clinical course of patients with aplastic anemia or myelodysplastic syndrome associated with persistent neutropenia. In: Hematological Oncology. 2012 ; Vol. 30, No. 2. pp. 82-88.
@article{9fef4f578e9c403f810a38417c8f812e,
title = "Clinical course of patients with aplastic anemia or myelodysplastic syndrome associated with persistent neutropenia",
abstract = "Patients with aplastic anemia (AA) or myelodysplastic syndrome (MDS) often have persistent severe neutropenia and are susceptible to infectious complications. We retrospectively reviewed the clinical course of patients with AA or MDS who had neutropenia (neutrophil count<500/μl) for more than 25days. A total of 46 patients, 11 with AA and 35 with MDS, were included. Twenty-three patients had infectious events (IE), and the cumulative incidence of IE was 30{\%} at 6months and 51{\%} at 1year. The cumulative incidence of IE was 67{\%} at 1year in 30 patients who experienced very severe neutropenia of less than 200/μl. Overall survival in all patients was 76{\%} at 6months and 65{\%} at 1year. In a multivariate analysis, male sex, underlying diseases, and a neutrophil count of less than 200/μl as a time-dependent covariate significantly affected IE. In analyses that excluded patients with AA, male sex was the only factor. In conclusion, severe neutropenia was significantly associated with IE in patients with AA or MDS, and IE might be lethal. When we only considered patients with MDS, the neutrophil count alone could not be used to predict the prognosis.",
keywords = "Aplastic anemia, Myelodysplastic syndrome, Neutropenia",
author = "Shinichi Kako and Hideki Nakasone and Hiroshi Endo and Kana Sakamoto and Masahiro Ashizawa and Miki Sato and Kiriko Terasako and Misato Kikuchi and Kimura, {Shun ichi} and Shinya Okuda and Rie Yamazaki and Kumi Oshima and Aki Tanihara and Junji Nishida and Kensuke Usuki and Yoshinobu Kanda",
year = "2012",
month = "6",
day = "1",
doi = "10.1002/hon.1001",
language = "English",
volume = "30",
pages = "82--88",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Clinical course of patients with aplastic anemia or myelodysplastic syndrome associated with persistent neutropenia

AU - Kako, Shinichi

AU - Nakasone, Hideki

AU - Endo, Hiroshi

AU - Sakamoto, Kana

AU - Ashizawa, Masahiro

AU - Sato, Miki

AU - Terasako, Kiriko

AU - Kikuchi, Misato

AU - Kimura, Shun ichi

AU - Okuda, Shinya

AU - Yamazaki, Rie

AU - Oshima, Kumi

AU - Tanihara, Aki

AU - Nishida, Junji

AU - Usuki, Kensuke

AU - Kanda, Yoshinobu

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Patients with aplastic anemia (AA) or myelodysplastic syndrome (MDS) often have persistent severe neutropenia and are susceptible to infectious complications. We retrospectively reviewed the clinical course of patients with AA or MDS who had neutropenia (neutrophil count<500/μl) for more than 25days. A total of 46 patients, 11 with AA and 35 with MDS, were included. Twenty-three patients had infectious events (IE), and the cumulative incidence of IE was 30% at 6months and 51% at 1year. The cumulative incidence of IE was 67% at 1year in 30 patients who experienced very severe neutropenia of less than 200/μl. Overall survival in all patients was 76% at 6months and 65% at 1year. In a multivariate analysis, male sex, underlying diseases, and a neutrophil count of less than 200/μl as a time-dependent covariate significantly affected IE. In analyses that excluded patients with AA, male sex was the only factor. In conclusion, severe neutropenia was significantly associated with IE in patients with AA or MDS, and IE might be lethal. When we only considered patients with MDS, the neutrophil count alone could not be used to predict the prognosis.

AB - Patients with aplastic anemia (AA) or myelodysplastic syndrome (MDS) often have persistent severe neutropenia and are susceptible to infectious complications. We retrospectively reviewed the clinical course of patients with AA or MDS who had neutropenia (neutrophil count<500/μl) for more than 25days. A total of 46 patients, 11 with AA and 35 with MDS, were included. Twenty-three patients had infectious events (IE), and the cumulative incidence of IE was 30% at 6months and 51% at 1year. The cumulative incidence of IE was 67% at 1year in 30 patients who experienced very severe neutropenia of less than 200/μl. Overall survival in all patients was 76% at 6months and 65% at 1year. In a multivariate analysis, male sex, underlying diseases, and a neutrophil count of less than 200/μl as a time-dependent covariate significantly affected IE. In analyses that excluded patients with AA, male sex was the only factor. In conclusion, severe neutropenia was significantly associated with IE in patients with AA or MDS, and IE might be lethal. When we only considered patients with MDS, the neutrophil count alone could not be used to predict the prognosis.

KW - Aplastic anemia

KW - Myelodysplastic syndrome

KW - Neutropenia

UR - http://www.scopus.com/inward/record.url?scp=84861832920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861832920&partnerID=8YFLogxK

U2 - 10.1002/hon.1001

DO - 10.1002/hon.1001

M3 - Article

C2 - 21692099

AN - SCOPUS:84861832920

VL - 30

SP - 82

EP - 88

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

IS - 2

ER -